Literature DB >> 28606813

Comparative Efficacy of Intramuscular and Scarification Routes of Administration of Live Smallpox Vaccine in a Murine Challenge Model.

A Phelps1, A J Gates1, L Eastaugh1, M Hillier1, D O Ulaeto2.   

Abstract

In recent years concern has mounted regarding the possibility of a re-emergence of smallpox through biowarfare or bioterrorism. There is also concern over the incidence of human monkeypox in endemic areas and the potential for monkeypox to be accidentally transported to non-endemic areas. In the event of re-emergence of smallpox or emergence of monkeypox, the accepted route of administration for live replicating smallpox vaccine is dermal scarification, which generates a virus-shedding lesion that persists for several days at the vaccination site. The lesion is a potential source of contact transmission of vaccine to individuals who may be contra-indicated for receipt of the live vaccine. In this study, we compare dermal scarification with intramuscular vaccination for replicating smallpox vaccine in a mouse lethal challenge model. Comparisons are made over multiple vaccine and challenge doses and data recorded for lethality, disease severity, and antibody responses. Qualitative and quantitative differences between the two routes are observed, and for the intramuscular route the febrile response is not suppressed after subsequent virulent vaccinia virus challenge. However both routes generate an immune response and protect from severe disease and death. Although dermal scarification is the preferred route of vaccination for the general population, intramuscular vaccination may be an option for people who are not contraindicated for the live vaccine, but who are close contacts of people who are contraindicated for the live vaccine, in an emergency situation. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Febrile response; Intramuscular vaccination; Monkeypox; Smallpox; Vaccinia

Mesh:

Substances:

Year:  2017        PMID: 28606813     DOI: 10.1016/j.vaccine.2017.05.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.

Authors:  Rakesh Kulkarni; Wen-Ching Chen; Ying Lee; Chi-Fei Kao; Shiu-Lok Hu; Hsiu-Hua Ma; Jia-Tsrong Jan; Chun-Che Liao; Jian-Jong Liang; Hui-Ying Ko; Cheng-Pu Sun; Yin-Shoiou Lin; Yu-Chiuan Wang; Sung-Chan Wei; Yi-Ling Lin; Che Ma; Yu-Chan Chao; Yu-Chi Chou; Wen Chang
Journal:  PLoS One       Date:  2021-09-09       Impact factor: 3.752

2.  Low-Temperature Multiple Micro-Dispensing on Microneedles for Accurate Transcutaneous Smallpox Vaccination.

Authors:  Sang-Gu Yim; Yun-Ho Hwang; Seonyeong An; Keum-Yong Seong; Seo-Yeon Kim; Semin Kim; Hyeseon Lee; Kang-Oh Lee; Mi-Young Kim; Dokeun Kim; You-Jin Kim; Seung-Yun Yang
Journal:  Vaccines (Basel)       Date:  2022-04-04

3.  Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.

Authors:  Sarah Reeman; Amanda J Gates; David J Pulford; Art Krieg; David O Ulaeto
Journal:  Viruses       Date:  2017-12-09       Impact factor: 5.048

4.  Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Alexei S Kabanov; Tatiana V Bauer; Leonid E Bulychev; Stepan A Pyankov
Journal:  Viruses       Date:  2020-07-24       Impact factor: 5.048

5.  The Influence of an Elevated Production of Extracellular Enveloped Virions of the Vaccinia Virus on Its Properties in Infected Mice.

Authors:  S N Shchelkunov; S N Yakubitskiy; T V Bauer; A A Sergeev; A S Kabanov; L E Bulichev; I A Yurganova; D A Odnoshevskiy; I V Kolosova; S A Pyankov; O S Taranov
Journal:  Acta Naturae       Date:  2020 Oct-Dec       Impact factor: 1.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.